| Literature DB >> 30519155 |
Shiwan Tao1, Mohammad Ridwan Chattun1, Rui Yan1, Jiting Geng1, Rongxin Zhu1, Junneng Shao2,3, Qing Lu2,3, Zhijian Yao1,4.
Abstract
Background: Sleep disturbances, such as early wakening, are frequently observed in patients with major depressive disorder (MDD). The suprachiasmatic nuclei (SCN), which controls circadian rhythm, is innervated by the raphe nucleus, a region where Tryptophan hydroxylase-2 (TPH-2) gene is primarily expressed. Although TPH-2 is often implicated in the pathophysiology of depression, few studies have applied a genetic and imaging technique to investigate the mechanism of early wakening symptom in MDD. We hypothesized that TPH-2 variants could influence the function of SCN in MDD patients with early wakening symptom.Entities:
Keywords: circadian disruption; early wakening; major depressive disorder; resting-state functional magnetic resonance imaging; tryptophan hydroxylase-2
Year: 2018 PMID: 30519155 PMCID: PMC6251472 DOI: 10.3389/fnins.2018.00827
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Demographic characteristics of subjects.
| Variables | MDD ( | HC ( | NWE ( | HC ( | WE ( | HC ( | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gender (male/female)a | 73/112 | 29/35 | 0.41 | 29/33 | 29/35 | 0.87 | 44/79 | 29/35 | 0.21 | |
| Family history (with/without) | 44/141 | 0/64 | – | 13/49 | 0/64 | – | 31/92 | 0/64 | – | |
| Marriage (married/not married)a | 109/76 | 37/27 | 0.88 | 31/31 | 37/27 | 0.38 | 78/45 | 37/27 | 0.46 | |
| Age (years)b | 33.38 ± 10.32 | 32.97 ± 9.78 | 0.78 | 31.47 ± 10.05 | 32.97 ± 9.78 | 0.40 | 34.34 ± 10.36 | 32.97 ± 9.78 | 0.38 | |
| Education (years)b | 13.48 ± 3.06 | 15.30 ± 2.86 | 0.00 | 13.65 ± 2.80 | 15.30 ± 2.86 | 0.00 | 13.39 ± 3.19 | 15.30 ± 2.86 | 0.00 |
Genotyping of TPH-2 variants.
| Variant | MDD | HC | OR (95% CI) | NWE | HC | OR (95% CI) | WE | HC | OR (95% CI) | HWE | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| rs4290270 | T | 185 (0.4162) | 64 (0.5469) | 1.716 (1.103–2.669) | 0.0167 | 62 (0.4597) | 64 (0.5469) | 1.489 (0.838–2.648) | 0.1750 | 123 (0.3943) | 64 (0.5469) | 2.027 (1.242–3.308) | 0.0047 | 0.1395 |
| A | 185 (0.5838) | 64 (0.4531) | 1.00 (ref) | 62 (0.5403) | 64 (0.4531) | 1.00 (ref) | 123 (0.6057) | 64 (0.4531) | 1.00 (ref) | |||||
| rs4570625 | G | 185 (0.4915) | 64 (0.5254) | 1.115 (0.722–1.730) | 0.6236 | 62 (0.5263) | 64 (0.5254) | 1.174 (0.688–2.005) | 0.5554 | 123 (0.5000) | 64 (0.5254) | 1.075 (0.668–1.732) | 0.7659 | 0.7942 |
| T | 185 (0.5085) | 64 (0.4746) | 1.00 (ref) | 62 (0.4737) | 64 (0.4746) | 1.00 (ref) | 123 (0.5000) | 64 (0.4746) | 1.00 (ref) | |||||
| rs11178998 | G | 185 (0.1595) | 64 (0.1797) | 1.087 (0.634–1.863) | 0.7626 | 62 (0.1855) | 64 (0.1797) | 0.971 (0.485–1.943) | 0.9335 | 123 (0.1463) | 64 (0.1797) | 1.181 (0.650–2.146) | 0.5855 | 0.6719 |
| A | 185 (0.8405) | 64 (0.8203) | 1.00 (ref) | 62 (0.8145) | 64 (0.8203) | 1.00 (ref) | 123 (0.8537) | 64 (0.8203) | 1.00 (ref) | |||||
| rs7305115 | G | 185 (0.4703) | 64 (0.5391) | 1.269 (0.823–1.956) | 0.2814 | 62 (0.5161) | 64 (0.5391) | 1.213 (0.695–2.117) | 0.4977 | 123 (0.4634) | 64 (0.5391) | 1.350 (0.838–2.178) | 0.2178 | 0.1291 |
| A | 185 (0.5297) | 64 (0.4609) | 1.00 (ref) | 62 (0.4839) | 64 (0.4609) | 1.00 (ref) | 123 (0.5366) | 64 (0.4609) | 1.00 (ref) | |||||
| rs41317118 | A | 185 (0.0703) | 64 (0.0625) | 0.992 (0.391–2.514) | 0.9857 | 62 (0.0645) | 64 (0.0625) | 0.787 (0.240–2.583) | 0.6925 | 123 (0.0732) | 64 (0.0625) | 0.981 (0.364–2.643) | 0.9691 | 1 |
| G | 185 (0.9297) | 64 (0.9375) | 1.00 (ref) | 62 (0.9355) | 64 (0.9375) | 1.00 (ref) | 123 (0.9268) | 64 (0.9375) | 1.00 (ref) | |||||
| rs17110747 | A | 185 (0.2450) | 64 (0.2188) | 0.920 (0.536–1.580) | 0.7617 | 62 (0.2177) | 64 (0.2188) | 0.976 (0.500–1.903) | 0.9420 | 123 (0.2520) | 64 (0.2188) | 0.854 (0.476–1.533) | 0.5971 | 1 |
| G | 185 (0.7550) | 64 (0.7812) | 1.00 (ref) | 62 (0.7823) | 64 (0.7812) | 1.00 (ref) | 123 (0.7480) | 64 (0.7812) | 1.00 (ref) |
A and T allele demographic distribution and pharmacotherapy.
| Variables | A allele ( | T allele ( | |
|---|---|---|---|
| Gender (male/female) | 17/41 | 44/56 | 0.068a |
| Family history (with/without) | 45/13 | 77/23 | 0.548a |
| Marriage (married/not married) | 23/35 | 42/58 | 0.453a |
| Age (years) | 34.40 ± 11.23 | 32.60 ± 9.62 | 0.134b |
| Education (years) | 13.09 ± 2.98 | 13.85 ± 2.94 | 0.496b |
| HAMD score | 27.90 ± 7.01 | 27.86 ± 7.64 | 0.372b |
| SSRI | 23 | 46 | – |
| SNRI | 14 | 21 | – |
| Others | 1 | 2 | – |
| Hypnotics | 36 | 63 | – |
| Medication free | 1 | 2 | – |
| Medication naive | 17 | 35 | – |
FIGURE 1(A) Brain regions showing significant functional connectivity differences between A allele and T carrier group with the right suprachiasmatic nuclei (SCN). The clusters with higher functional connectivities are shown in yellow and red (p < 0.001, AlphaSim corrected). (I) The right fusiform gyrus. (II) The right middle frontal gyrus. (B) Brain regions showing significant functional connectivity differences between A allele and T carrier group with the left suprachiasmatic nuclei (SCN). The clusters with lower functional connectivities are shown in blue (p < 0.001, AlphaSim corrected). (III) The right lingual gyrus. (IV) The left calcarine sulcus. The MNI coordinates are shown above each slice.
Functional connectivity of regions of interest (ROIs).
| Brain regions | BA | Cluster size | Peak MNI coordinates | Peak | ||
|---|---|---|---|---|---|---|
| Fusiform_R | 20 | 8 | 34 | -4 | -44 | 3.5765 |
| Frontal_Mid_R | 46 | 6 | 50 | 46 | 4 | 3.7615 |
| Lingual_R | 30 | 16 | 12 | -60 | 6 | -4.138 |
| Calcarine_L | NA | 6 | -26 | -58 | 6 | -3.7248 |